FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1

House Republicans Want GAO Lab Safety Review

House Energy and Commerce Committee Republicans ask for a GAO review of laboratory safety in FDA, CDC, and NIH, citing previous GAO recommendations th...

Medical Devices

FDA Warns Taiwanese, Australian X-ray Firms

FDA warns two firms in Taiwan and Australia about Quality System violations in their manufacturing of x-ray equipment.

latest-news-card-1
Human Drugs

Complete Response Letter on Ocaliva sNDA

FDA sends Intercept Pharmaceuticals a complete response letter on its supplemental NDA for Ocaliva (obeticholic acid) seeking to convert its accelerat...

latest-news-card-1
FDA General

Disappointed Califf on Possible Disruption at FDA

FDA commissioner Robert Califf tells Friends of Cancer Researchs annual meeting that he is personally disappointed in the election results and the pot...

latest-news-card-1
Human Drugs

Lilly Opposes Tirzepatide Bulks List Nomination

Lilly calls on FDA to reject the Outsourcing Facilities Association nomination of tirzepatide to be on the 503 Bulks List so it can be compounded.

latest-news-card-1
Biologics

Clinical Hold on Novavax Vaccines Lifted

FDA removes a clinical hold on a Novavax IND for its Covid-19-influenza combination and stand-alone flu vaccine candidates.

latest-news-card-1
Biologics

Autolus Wins OK for Leukemia CAR-T Theray

FDA approves an Autolus Therapeutics BLA for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy for treating adult patients with lymphoblastic leukem...

latest-news-card-1
Human Drugs

Safety Issue Prompts Zelnecirnon Termination

Rapt Therapeutics terminates its zelnecirnon drug development program due to a serious liver safety issue.

latest-news-card-1
Human Drugs

J&Js Nipocalimab Gets Breakthrough Status

FDA grants Johnson & Johnson a breakthrough therapy designation for nipocalimab and its use for treating Sjgren's disease.

latest-news-card-1
Human Drugs

Disappointing Data in Schizophrenia Drug: AbbVie

AbbVie says its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia did not...